# Merck sees pivotal victory for $3B eye disease prospect

> **Newsylist Open Intelligence Dossier** · First detected: 2026-09-25 01:29 UTC · Category: Business · Sources: 6 · Current Velocity: 3.67

## Key People, Organizations & Locations
Merck

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| FirstWord | Merck & Co.'s Wnt drug wins in ophthalmology study, but safety concerns crop up | 2026-09-24 12:15 | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTFBBOEFrcGRNX1gyVE1KX0pod1lSVXNPdzA2Ml9QaDNscVdTSDQ0Z05HUXVDdVpnYnRKTTlDRzNEbW5nRmZNVnBEaE8tRHEwT3d2QWlJ?oc=5) |
| Ophthalmology Times | Remigromig noninferior to ranibizumab in phase 2b/3 BRUNELLO DME trial - Eye Care Network | 2026-09-24 12:15 | [Source Link](https://news.google.com/rss/articles/CBMipwFBVV95cUxPNjI5aDJLWV8xWTk3eXRpVThha0lsYUwzLUxMVHVSYk14RkcteHQ2U2R6eVZ5NkJDb1VFRU5tT3NaVDhVQ2M5ckNObTlwcEtXbm1xTTJ0YnI1MFE5enpMdThKQ2djTkRFUk5wc1Zma1cyUkFjSHpyNVdKS3RXTmE2MFc3aGowTUZ6clJzSGRCZFI2ajlKZFNZVzFfWE80eVU5VzJydXYzQQ?oc=5) |
| Business Wire | Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema | 2026-09-24 12:15 | [Source Link](https://news.google.com/rss/articles/CBMi6AJBVV95cUxNRFZISlVucDdYUXBVaWRTXzRuNE1xWC1WUEwwNzB0ZTZNQjM0ZkZQOUlYQkk4a3A1N2VleW1FZFQ2eXVYQ0pTS3N6NDI2N3ZzbnRMU3FYb1VQOGhfcTBFaTlhNWpxRzJ5VC1yOXFLWDdnVFhGeE50T0t4aDJRQkxKX3M2UlZHSnQ3ZW52YmIzY3NOQmp3cExkVGNYNjFYMU1QTzJ1Z0Rscm9aRHVMV0tOY09sbkRhZndRSGhUbU1hbGJYOGVXNGNpSG1RSmFsVWY0YTZsZXZmdFVaOUVnOHAtNFBuSEx4dW85OE9qaTdrVklCU0hEaDhHcVF2X1Y2N1F6RTJtbHRTMURVbFlzNXZDdlI4WnMtYVhRVXFyVWY5dFVhZzRWc2NFRXZoV01uRkw5bzNzREJFNFRzUWhzWEFQSFdwcGVyMDM5dUVLdXVpZzhsLUd1OVd) |
| Endpoints News | Merck’s return to ophthalmology snags first success | 2026-09-24 12:15 | [Source Link](https://news.google.com/rss/articles/CBMif0FVX3lxTE9lZEpFQk5jNC01RTUyS0xVY1BHeHFtYk93RVg2LWFFVndFQjJCZGZCNzBLUGlCWUhfcWRUYllnLTAtTWsxZmIzX0FzVU1KVWQzX3FoNS1WeDNnTmpPbXktXzRfMkZvdGw2VkJNVWVPeUxMcHFVUjNvc09BSU93cWs?oc=5) |
| Reuters | Merck's drug for diabetes-related eye disease meets trial goal | 2026-09-24 12:15 | [Source Link](https://news.google.com/rss/articles/CBMiuAFBVV95cUxQd3JwRm1OSGhUUHQ2V3dvRlBYbGVXb2kzQjBWa2tqbF9STlZXYUpWVmVZa1FFQmI4V0VlbEZDbmp2NUVDdkQtYmUzODBWYTZ2Z01fdF9Zb3NiaDlFU0F3ZVVkMV9scnVOcGdJS2c3bUpfT1JhRUlyNE5LQnNxLXJHMDlab2ZYampFNk1EdjZPVk93dTFEX25mZFF1QThzMUFXc3BjZV90UzEyZjNpWktxTzVraC05dXN6?oc=5) |
| Fierce Biotech | Merck sees pivotal victory for $3B eye disease prospect | 2026-09-24 12:15 | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxNdFBLeUMxU0s4M2hxLTNGY2VNbjdObWZiU0JfUmRERUhNUzU5NUVMZWNNN2hPV2UwUk9WdkJIYU50NUZUdW4xWjdhaU81LURIN2lRTW1EdkhTMHc1MFNydFpMWGZTSWI1bGRoeHAtdnRzZlJrMUFkZmhxMGQzczNHWDhQVUFhU1phLTA2MWduOTBFNE9RTWJkdDJR?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-09-25/merck-sees-pivotal-victory-for-3b-eye-disease-prospect*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*